Trodelvy (sacituzumab govitecan)

Numéro de dossier de l’APP: 22577

État des négociations:

Négociation envisagée

Indication(s):

The treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.

Promoteur/fabricant:

Gilead Sciences Canada Inc.

Numéro de projet de l’ACMTS:

PC0323-000

Lettre-contrat de l’APP:

Sans objet

Conclusion du processus de négociation:

Sans objet